ABOUT PRECISION ADVANCE

Since 2013, Precision’s interdisciplinary teams have been advancing clinical, manufacturing and commercialization solutions to help innovators transform patient lives. We know that delivering a cell or gene therapy to market requires a nuanced, comprehensive and integrated approach, scientific and manufacturing expertise, and the right partner. That’s precisely why we’ve launched Precision ADVANCE, a collection of interconnected services and complementary teams uniquely focused on the complexities of clinical, regulatory, manufacturing, and commercial needs to successfully bring cell or gene therapies to market.

WEBINARS

  • In this webinar co-sponsored by Precision ADVANCE and Project Farma, a panel of industry experts discuss the challenges faced when building a cutting-edge cell therapy manufacturing facility.

  • Considerations for the Clinical Development of Cell & Gene Therapies is a 2-part panel discussion with our Precision experts and C-Suite leaders from advanced therapy companies on the front lines of development. Part 1 discusses Cell Therapy development, and Part 2 discusses Gene Therapy development.

  • In this Precision ADVANCE panel, industry experts share perspectives on the current state of the cell and gene therapy industry and provide key insights in shortening time-to-market for advanced therapies.

  • In this webinar, Carolyn Morgan of PRECISIONeffect moderates an expert panel exploring the challenges of commercializing a cell or gene therapy from industry trailblazers that share lessons learned from prior launches and discuss how cell and gene therapies are reshaping commercializing strategies. Some of the topics explored will be tensions between cost-effectiveness and affordability, evidence generation strategies and development, and communication to payers and health technology appraisal organizations.

VIDEOS

PODCASTS

  • Rare disease trials are complex under the best of circumstances—and the coronavirus pandemic has only complicated things. In this podcast, Precision’s Thijs Opdeweegh, Director, Clinical Business Solutions, and Kristi Clark, Senior Vice President, Project Management and Clinical Operations, explore the impact of decentralized operations on rare disease patients, and which new approaches are likely to become the “new normal” after COVID.

CONTACT INFORMATION

Precision ADVANCE

2 Bethesda Metro Center, Suite 850

Bethesda, MD 20814

UNITED STATES

Contact: Asha Strazzero-Wild